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MetastasisQualitative alterations or abnormal expression of microRNAs (miRNAs) in colorectal cancer has mainly been
demonstrated in primary tumors. The miRNA expression proﬁles in 78 samples from 46 patients were analyzed
to identify changes in miRNA expression level among normal colon mucosa, primary tumor and liver metastasis
samples. Using this dataset, we describe the interplay ofmiRNA groups in regulating pathways that are important
for tumor development. Here we describe in details the contents and quality controls for the miRNA expression
and clinical data associated with the study published by Pizzini and colleagues in the BMC Genomics in 2013
(Pizzini et al., 2013). Data are deposited in GEO database as GSE35834 series.
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Study population and clinical data
For this study [1], 46 patients with sporadic colorectal adenocar-
cinomas (CRC), who underwent surgery at the University of Padova
(Surgery Unit, Department of Surgery, Oncology and Gastroenterology)
between March 1994 and September 2008, were selected from the
institutional CRC database. Patients with a known history of a hereditary
colorectal cancer syndromewere excluded. The Ethics Committee of the
University Hospital of Padova approved the study. All patients provided
written informed consent. Enrolled patients did not receive any
neo-adjuvant treatment. Table 1 lists the main patient and tumor
characteristics. Normal mucosa samples were taken at a minimum
distance of 10 cm from the tumor site. All samples were immediately
snap-frozen in liquid nitrogen and stored at−80° until use.the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
Table 1
Patients data.
Characteristics
No of patients (n) 46
Age (years, mean ± s.d.) 60,7 ± 10,2
Sex
Female 17
Male 29
Tumor site
Cecum, colon ascending, transverse colon 13
Splenic [left] ﬂexure, colon descending, sigmoid colon 20
Rectum 13
TNM stage IV
Liver metastasis
Synchronous 39
Metachronous 7
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We selected 78 samples comprising 23 normal colonmucosa (N), 31
primary tumors (T) and 24 liver metastases (M). This dataset included
24 samples belonging to 8 patients with three matched samples (T, N
and M from the same patient) as detailed in Table 2.
7 μm sections from each tissue sample were prepared using a Leica
CM 1950 cryostat (Leica Microsystems, Wetzlar, Germany) and hema-
toxylin and eosin stained; sections of each specimen were prepared
and re-evaluated by one experienced pathologist; only samples with
more than 80% of vital tumor tissue were considered for RNA extraction
in toto. Laser microdissection was performed on a few frozen samples of
primary tumors and metastases with a proportion of neoplastic cells
lower than 80% using LMD-6000 Laser Microdissection System (Leica
Microsystems,Wetzlar, Germany). Total RNA from samples was isolated
using Trizol (Life Technology Corp, Carlsbad, CA, USA) according to
manufacturer's instructions. RNA concentration was quantiﬁed on a
NanoDrop 1000 spectrophotometer (NanoDrop Technologies, Waltham,
MA, USA) and RNA quality was evaluated by RNA 6000 Nano LabChip
(Agilent Technologies, Santa Clara, CA, USA) on an Agilent 2100
Bioanalyzer. Samples with RNA integrity number (RIN) b6 were
excluded.
miRNA microarray hybridization was performed from total RNA
with the Affymetrix GeneChip miRNA Array 2.0 (Affymetrix Santa
Clara, CA, USA). Brieﬂy, 100 ng of total RNA from each sample was
labeledwith the FlashTag Biotin RNA Labeling Kit (Genisphere, Hatﬁeld,
PA, USA), hybridized according tomanufacturer's instructions, and then
scanned with an Affymetrix GCS 3000 7G scanner.
Quality control and normalization
A ﬁrst quality control check was performed on miRNAs arrays, with
Affymetrix® Expression Console™ software (v.1.0) to determine the
success of hybridizations. miRNA expressionmeasurewas reconstructed
from. cel ﬁles by using the Robust Multichip Average (RMA) method
implemented in the Bioconductor R package affy [2,3].Table 2
Sample set description for miRNA array dataset. Column two indicates the number of
patients for which we obtained paired data for different tissue types combinations; last
column reports the total number of samples for each tissue type.
Match type Number of patients Tissue type Number of samples
N-T-M 8 N 23
N-T 7
T-M 8 T 31
M-N 2
N 6 M 24
T 8
M 6 Total 78
Total 45Quality control of samples was carried out with R software. Three
descriptive plots (MA-plot, NUSE plot and RLE plot) were generated
for each sample using a customized version of the Array Quality Metrics
Bioconductor package [4].
MA-plots evaluate the dependency between intensity levels and
expression ratios comparing expression data coming from one chip to
a pseudo-median chip of the dataset. The shape of the point cloud and
the loess curve interpolating the cloud is examined under the hypothe-
sis that the majority of points should stay near the x-axis and loess
curve should be straight and parallel to the x-axis. RLE (Relative Log
Expression) plots are box plots of values computed for each probeset
by comparing the expression value on each array against the median
expression value for that probeset across all arrays. Potential outlier
chips are identiﬁed as boxes not centered on 0 or more spreadout
than the others.
NUSE plots (Normalized Unscaled Standard Error) are box plots of
normalized standard errors obtained by ﬁtting probe linear models as
in RMA. An array with elevated standard errors relative to the other
arrays is typically of suspect quality. Samples that were considered of
low quality were excluded from further analysis. miRNAs detected in
fewer than 20 samples were discarded, without ﬁltering out miRNAs
undetected only in one sample class.
Data are available at the GEO database [5] as GSE35834 series.
Basic analysis
Unsupervised clustering
Unsupervisedhierarchical cluster analysiswas performed on selected
miRNAs expression data, using Pearson Correlation-based distance and
average clustering. Normal samples clustered together and were rela-
tively well separated from T and M samples. Considerable per-patient
pairing of T and M samples was observed in the dendrogram (Fig. 1),
in which triplets and pairs of samples from the same patient are shown
in the same color. In roughly 25% of patients, the M samples were
more similar to the T fromwhich it derives, rather than to theM samples
of other patients (20% of per-patient sample pairing, in miRNA-based
heatmap).
Paired vs unpaired comparisons
A Signiﬁcance Analysis of Microarrays (SAM) [6] with unpaired and
paired two-class designwasperformed in parallel to identify differences
in miRNA expression between groups of N, T and M samples.
In the larger unpaired dataset, we identiﬁed 62, 63 and 11 DEMs
(Differentially Expressed miRNAs) in T vs N, M vs N andM vs T compar-
isons, respectively (Supplementary Table 1). Several miRNAs were
signiﬁcantlymodulated inmore than one contrast. Only 5miRNAs varied
merely when unpaired M and T samples were compared (miR-146a,
miR-15a, miR-15b, miR-196a, miR-708). Of 53 DEMs shared by at least
two unpaired comparisons, 25 were always under- and 26 over-
expressed, whereas two miRNAs did not follow the same trend in the
various comparisons. In both T vs N and M vs T contrasts, we observed
a comparable number of up- and down-modulated DEMs: 29 and 33
were respectively up- and down-modulated in T vs N; as against 5 and
6 in M vs T. Regarding global miRNA expression, when we considered
the distribution of all DEM expression levels measured in N, T and M,
again we could not ﬁnd any signiﬁcant differences between the groups
(mean values 6.10, 5.95 and 6.01, respectively; p-value of pairwise
mean equality t-test N 0.7).
Differentially expressed miRNA in pairwise group comparisons, in-
volving groups of samples matched per patient (e.g., T vs N samples
matched per patient) was calculated with SAM using a two-class paired
design. The cut-off for signiﬁcance (determined by tuning parameter
delta) corresponded to a false discovery rate (FDR) b 0.01. Sample sub-
sets matched by patient with miRNA expression data were considered
for paired comparisons (e.g., subset of T vs N samples, with T and N
from the same patient). We found 34, 38 and 5 DEMs, respectively in
Fig. 1. Sample classiﬁcation and heatmap based on 309 miRNAs expression proﬁle. Color-coding of samples reported in three different lines refers to different information. First line
indicates tissue type (N, T and M) as shown in the legend. The two lines below indicate the per-patient matching of samples, separately for triples (upper line) and couples (lower
line) of samples from the same patient (i.e. samples from the same patient are in the same color).
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miR-210, hsa-miR-150, hsa-miR-100 and hsa-miR-122 as miRNAs
involved in M vs T comparison.
Most DEMs identiﬁed with the paired test were conﬁrmed with the
unpaired test conducted on the larger dataset, as shown in Fig. 2 (top
panel) which, for each comparison, gives the numbers of DEM obtained
with paired and unpaired designs, and intersections thereof.
DEMs between tumor and normal mucosa include ones previously
described as members of a “signature” common to various types of
solid tumors. Many of them have also been implicated in the molecular
and biological processes driving tumorigenesis in CRC.
miRNAs involved in EMT
Of 82 miRNAs modulated during tumor progression, 22 were in-
volved in EMT (Epithelial to Mesenchymal Transition), a critical step
which drives tumor metastasis [7]: 19 were differentially expressed in
T vs N and one in M vs T, and one was common to both comparisons.
We observed that the expression of many DEMs involved in EMT wasFig. 2. Venn diagrams of intersections among DEMs obtained with differing contrasts and
methods. Top: overlap of DEMs in same contrast (e.g., T vs N) with paired and unpaired
tests; bottom: overlap among DEMs obtained by the same test, with differing contrasts.modulated in tumor development (T vs N comparison) and then
remained stable or at a similar level in metastasis.
Fig. 3 shows the expression proﬁles of 22 miRNAs involved in EMT
which were differentially expressed in TN and/or MT comparisons.
miR-10b and potential association with survival
We investigated the association between the expression levels of
26 DEMs (present in reconstructed post-transcriptional regulatory
networks) in biopsies obtained from distinct primary [n = 26] or met-
astatic [n=20] colorectal cancers andpatients' disease-speciﬁc survival
(interval between diagnosis of primary or metastatic disease and death
by disease or last follow-up).
Given the relatively low sample size, only univariate survival analy-
sis was performed, and the Cox proportional hazard regression model
was used, assuming a linear functional form of the covariates being
assumed. The risk associated with a unit increase in miRNA levels was
expressed as hazard ratio (HR) and its 95% conﬁdence interval (CI).
With Bonferroni's p-value adjustment for multiple comparisons, the
alpha level of signiﬁcancewas set at 0.002. In order to illustrate progno-
sis associated with different levels of the relevant miRNAs, Kaplan–
Meier survival curves were generated after dichotomizing (high vs
low categories) originally continuous covariates based on the median
values of miRNA expression levels. All analyses were performed with
Stata/SE software (version 11.0, StataCorp LP, College Station, TX,
USA). The 26 miRNAs included in the T vs N and M vs T networks
were considered for survival analysis.
The expression of miR-10b measured in liver metastasis showed a
statistically signiﬁcant association with the survival of patients affected
with stage IV CRC (hazard ratio = 1.47, 95% conﬁdence interval =
1.23–1.75; adjusted p-value: 0.00052). The effect of miR-10b on prog-
nosis is given in Fig. 4, which shows that patients with high levels of
miR-10b expression in their metastatic disease have a shorter time to
event (median survival: 8 months) compared with those with low
levels (51 months). In our study, the expression levels of miR-10b
measured in primary tumors had no signiﬁcant impact on prognosis.
Discussion
SeveralmiRNAs signiﬁcantly differentially expressed (DEMs) during
tumor progression were identiﬁed. The whole set of samples with
miRNA expression data was considered in unpaired tests (e.g., all T vs
Fig. 3. Expression proﬁles in considered sample classes of 22 miRNAs reportedly involved in EMT that are differentially expressed in the TN and/or MT comparisons.
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considered for paired comparisons (e.g., subset of T vs N samples, with
T and N from the same patient). Identiﬁcation of DEM conﬁrmed thatFig. 4. Kaplan–Meier overall survival curve was plotted based on miR-10b expression
showing relationship between miR-10b expression and survival in CRC cancer.more miRNAs are modulated in N vs T than in T vs M transitions; how-
ever, DEMs in metastasis compared with primary tumors may be of
great importance since they include key regulators of several processes
relative to disease progression. Almost all of the miRNAs which vary
their expression in the N vs T transition remain stable after metastasis
development; three-quarters of miRNAs modulated in the T vs M tran-
sition are invariant in the N vs T transition [8–11]. Although purely
exploratory in nature, due to the relatively low number of subjects ana-
lyzed, our data support the prognostic value of miR-10b, in line with
available evidence regarding the role played by this microRNA in cancer
biology, according to both preclinical and clinical models. miR-10b
over-expression has been associated not only with enhanced aggres-
siveness of malignant cells in a variety of experimental models, but
also with worse prognosis in patients with breast and pancreatic carci-
noma. To our knowledge, our results suggest the potential involvement
of this microRNA in CRC, with special regard to the modulation of the
biological behavior of metastatic disease.
Supplementary data to this article can be found online at BMC
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